Risk factors for loss to follow‐up after the start of direct‐acting antiviral treatment for hepatitis C virus infection

BACKGROUND AND AIM: Direct‐acting antivirals (DAAs) have recently been developed to treat hepatitis C virus (HCV) infection. Additionally, interferon‐free DAA treatment has improved liver function and reduced the risk of hepatocellular carcinoma (HCC) following HCV eradication. Previous studies on H...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuwano, Akifumi, Yada, Masayoshi, Kurosaka, Kazuki, Tanaka, Kosuke, Masumoto, Akihide, Motomura, Kenta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958342/
https://www.ncbi.nlm.nih.gov/pubmed/36852151
http://dx.doi.org/10.1002/jgh3.12855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958342/
https://www.ncbi.nlm.nih.gov/pubmed/36852151
http://dx.doi.org/10.1002/jgh3.12855

Ejemplares similares